Trial reportInternational journal of molecular sciences2026
Beta-Glucan Supplementation Improves Clinical Outcomes and Preserves Immune Homeostasis in Patients with Advanced Solid Tumors Receiving Chemotherapy: A Prospective Phase II Randomized Three-Arm Clinical Trial.
Trial report in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced immune dysregulation remains a major challenge in patients with advanced solid tumors. β-Glucan has been reported to possess immunomodulatory properties; however, its longitudinal effects on immune homeostasis during chemotherapy remain unclear. In this prospective, randomized phase II study, patients receiving chemotherapy were assigned to receive β-glucan powder (with L-glutamine and bioactive protein from bovine colostrum), β-glucan capsules (with L-glutamine), or standard care. Clinical outcomes, serial hematologic parameters, longitudinal immune profiling, and an in vitro Jurkat T-cell viability assay were evaluated. Compared with controls, β-glucan supplementation improved the disease control rate, accelerated neutrophil recovery, and maintained a more stable neutrophil-to-lymphocyte ratio during chemotherapy. Longitudinal immune profiling demonstrated greater stability of T-cell, NK-cell, NKT-cell, and KIR (CD158)-expressing immune-cell populations in β-glucan supplementation groups, suggesting attenuation of chemotherapy-induced immune remodeling. Both β-glucan formulations showed comparable immunomodulatory effects, although the expression of CD158b(+) and CD158i(+) NK-cell subsets remained more stable in the powder group during later treatment. In vitro, β-glucan significantly reduced Jurkat T-cell viability, indicating direct biological activity in addition to its clinical immunomodulatory effects. These findings suggest that β-glucan supplementation helps preserve immune homeostasis during chemotherapy and may serve as a promising adjunctive immunonutritional strategy for patients with advanced solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.